Compare Hewlett Packard Enterprise Co (HPE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Incyte Corporation — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Hewlett Packard Enterprise Co is far larger — about 4.1× Incyte Corporation's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Incyte Corporation for 33 Days on average.
| HPE | INCY | |
|---|---|---|
Market Cap | $94.25B | $22.85B |
Volume | 16,060,854 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $73.46 | $129.93 |
52-Week Low | $20.01 | $83.80 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $108.28B | $18.35B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock trades at $70.99, down 1.56% today but near its 52-week high, with a bullish technical outlook and strong AI-driven momentum. Recent earnings beats and a $1.2B AI server order from Vultr highlight robust demand. Valuation metrics show a P/E of 36.6 and P/S of 2.4, while cash flow trends indicate volatility with a net outflow of $9.25B in 2025 but a projected rebound in 2026.
The outlook is positive, driven by AI infrastructure growth and raised guidance, but risks include high debt levels and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting cautious optimism amid near-term overbought conditions.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
